Drugs / STAPULDENCEL
STAPULDENCEL
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05277753 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05262673 | Jun 2026 → Dec 2029 expected | B-cell acute lymphoblastic leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04085159 | Jun 2026 → Dec 2029 expected | cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06739226 | Aug 2025 → Dec 2028 expected | melanoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03514836 | May 2018 → Jan 2021 | castration-resistant prostate carcinoma | SOTIO a.s. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02470468 | Dec 2014 → Jan 2018 | non-small cell lung carcinoma | SOTIO a.s. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT04834544 | Apr 2021 → Oct 2024 overdue | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Peking University Third Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03657966 | Nov 2017 → Nov 2020 | ovarian carcinoma | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02107378 | Jan 2014 → Aug 2016 | malignant epithelial tumor of ovary | SOTIO a.s. | Terminated | No outcome recorded |
| Phase 2 | NCT02137746 | Dec 2013 → Apr 2015 | prostate cancer | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02107937 | Nov 2013 → Nov 2020 | malignant epithelial tumor of ovary | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02107950 | Nov 2013 → Nov 2016 | malignant epithelial tumor of ovary | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02107404 | Apr 2012 → Jun 2015 | prostate cancer | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02107391 | Mar 2012 → Dec 2015 | prostate cancer | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02107430 | Mar 2012 → Sep 2013 | prostate cancer | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT02105675 | Feb 2012 → Mar 2014 | metastatic prostate carcinoma | SOTIO a.s. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03905902 | Aug 2021 | fallopian tube cancer, ovarian cancer, peritoneal carcinoma | SOTIO a.s. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02111577 | May 2014 → Jan 2020 | castration-resistant prostate carcinoma | SOTIO a.s. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STAPULDENCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544995 ↗ |
| Known as | DCVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02470468 ↗ |
| Known as | DCVAC/LuCa | “Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer” NCT02470468 ↗ |
| Known as | DCVAC/OvCa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657966 ↗ |
| Known as | DCVac/Pca | “DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy.” NCT03514836 ↗ |
| Known as | Estapuldencel | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544995 ↗ |
| Known as | Stapuldencel-t | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544995 ↗ |
| Action | Activate | “The dendritic cell (DC) vaccine leverages DC to activate T cells that specifically recognize target antigens” NCT06739226 ↗ |
| Modality | Cell therapy | “Active Cellular Immunotherapy” NCT02105675 ↗ |
| Route | Subcutaneous | “DCVAC/PCa or placebo was administered subcutaneously every 3 to 4 weeks (up to 15 doses).” PMID 35142815 ↗ Apr 2022 |